Cost-effectiveness of Intravitreal Ranibizumab With Verteporfin Photodynamic Therapy Compared With Ranibizumab Monotherapy for Patients With Polypoidal Choroidal Vasculopathy

IMPORTANCE: The EVEREST II trial showed that for patients with polypoidal choroidal vasculopathy (PCV), intravitreal ranibizumab in combination with verteporfin photodynamic therapy improves visual acuity relative to ranibizumab monotherapy. However, whether combination therapy is incrementally cost...

Celý popis

Uloženo v:
Podrobná bibliografie
Vydáno v:JAMA Ophthalmol
Hlavní autoři: Doble, Brett, Finkelstein, Eric Andrew, Tian, Yubing, Saxena, Nakul, Patil, Shiva, Wong, Tien Yin, Cheung, Chui Ming Gemmy
Médium: Artigo
Jazyk:Inglês
Vydáno: American Medical Association 2020
Témata:
Original Investigation
On-line přístup:https://ncbi.nlm.nih.gov/pmc/articles/PMC6990685/
https://ncbi.nlm.nih.gov/pubmed/31917395
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1001/jamaophthalmol.2019.5628
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!

Podobné jednotky